AISIO (Artificial Intelligence Services in Oncology). It is a Non-Profit Service that will offer Artificial Intelligence applications in Molecular Oncology. More specifically, it will offer a) Whole Genome Sequencing in pediatric oncology patients with solid tumors, b) RNA-Seq in pediatric patients with Acute lymphoblastic leukemia, c) Neoantigen prediction panels in metastatic oncology patients with the application of Tumor Whole Exome Exole Sequencing, Normal Whole Sequencing, Tumor RNA-Seq and artificial intelligence.
The above molecular tests will be performed in collaboration with internationally accredited diagnostic centers, which are CAP certified, such as BGI, and patients will only be charged the cost of sequencing the genetic material. Best Practices Algorithms will be used for the analyzes, such as a) the Google Tensorflow Artificial Intelligence Algorithm, b) the Machine Learning-based Classifier for the RNA-seq based Gene Expression classifier, which includes Gene Fusion analysis, for patient categorization with ALL. c) algorithms for predicting Neoantigens, ie peptides resulting from genetic changes in the tumor that "stimulate" the immune system.
Neoantigens, arising from somatic mutations and specifically targeting tumor cells, have the potential to stimulate a highly specific immune anti-tumor response. Technological advances such as genomic sequencing and bioinformatics algorithms for epitope prediction have directly facilitated the development of neoantigen vaccines for individual cancers.